Erratum: Update to living WHO guideline on drugs for covid-19 (BMJ (2020) 370 (m3379) DOI: 10.1136/bmj.m3379);A living WHO guideline on drugs for covid-19

BMJ

Volumn 370, Issue , 2020, Pages

  Lamontagne, François ^a,b   Agoritsas, Thomas ^c,d,e   MacDonald, Helen ^f   Leo, Yee Sin ^g   DIaz, Janet ^h   Agarwal, Arnav ^c,e,i   Appiah, John Adabie ^j   Arabi, Yaseen ^k   Blumberg, Lucille ^l   Calfee, Carolyn S ^m   Cao, Bin ⁿ   Cecconi, Maurizio ^o,p   Cooke, Graham ^q   Dunning, Jake ^r   Geduld, Heike ^s   Gee, Patrick ^t   Manai, Hela ^u   Hui, David S ^v   Kanda, Seema ^c   Kawano Dourado, Leticia ^w   Kim, Yae Jean ^x   Kissoon, Niranjan ^y   Kwizera, Arthur ^z   Laake, Jon Henrik ^aa   MacHado, Flavia R ^ab   Qadir, Nida ^ac   Sarin, Rohit ^ad   Shen, Yinzhong ^ae   Zeng, Linan ^c,e,af   Brignardello Petersen, Romina ^c,e   Lytvyn, Lyubov ^c,e   Siemieniuk, Reed ^c,e   Zeraatkar, Dena ^c   Bartoszko, Jessica ^c   Ge, Long ^c,ag   Maguire, Brittany ^ah   Rochwerg, Bram ^c   Guyatt, Gordon ^c,e,ai   Vandvik, Per Olav ^e,aj   Natalia, Pshenichnaya ^c   more..

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e The MAGIC Evidence Ecosystem Foundation   (Norway)

^f British Medical Journal Technology Assessment Group   (United Kingdom)

^g NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^k KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^l NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^o HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^p HUMANITAS UNIVERSITY   (Italy)

^q IMPERIAL COLLEGE LONDON   (United Kingdom)

^r PUBLIC HEALTH ENGLAND   (United Kingdom)

^s UNIVERSITY OF STELLENBOSCH   (South Africa)

^t Faculty of Medicine ^*  (United States)

^u UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^v CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^w UNIVERSITY OF SÃO PAULO   (Brazil)

^x Sungkyunkwan University School of Medicine   (South Korea)

^y UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^z MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^aa OSLO UNIVERSITY HOSPITAL   (Norway)

^ab FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad NATIONAL INSTITUTE OF TUBERCULOSIS AND RESPIRATORY DISEASES   (India)

^ae FUDAN UNIVERSITY   (China)

^af SICHUAN UNIVERSITY   (China)

^ag LANZHOU UNIVERSITY   (China)

^ah UNIVERSITY OF OXFORD   (United Kingdom)

^ai UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^aj UNIVERSITY OF OSLO   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE;

ARTICLE; CLINICIAN; CONSENSUS; CORONAVIRUS DISEASE 2019; DECISION MAKING; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HEALTH CARE SYSTEM; HUMAN; HUMAN RIGHTS; INVASIVE VENTILATION; MEDICAL EXPERT; MORTALITY RISK; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRAM ACCEPTABILITY; STANDARD; UNCERTAINTY; WORLD HEALTH ORGANIZATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; PANDEMIC; VIRUS PNEUMONIA;

ADRENAL CORTEX HORMONES; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; WORLD HEALTH ORGANIZATION;

EID: 85090506720     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.n860     Document Type: Erratum

References (17)

1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2020. https://covid19.who.int/.
2. Maguire BJ, Guérin PJ. A living systematic review protocol for COVID-19 clinical trial registrations. Wellcome Open Res 2020;5:60. doi: 10.12688/wellcomeopenres.15821.1 pmid: 32292826
3. Siemieniuk RAC, Bartoszko JJ, Ge L, etal. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020;370:m2980. doi: 10.1136/bmj.m2980. pmid: 32732190
4. World Health Organization. Handbook for guideline development. 2008. https://www.who.int/publications/guidelines/handbook_2nd_ed.pdf?ua=1.
5. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees PBoard of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med 2012;156:525-31. doi: 10.7326/0003-4819-156-7-201204030-00009 pmid: 22473437
6. TheWHORapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020; doi: 10.1001/jama.2020.17023.
7. Ye Z, Wang Y, Colunga-Lozano LE, etal. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020;192:E756-67. doi: 10.1503/cmaj.200645 pmid: 32409522
8. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, etal. Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Crit Care Med 2018;46:1411-20. doi: 10.1097/CCM.0000000000003262. pmid: 29979221
9. World Health Organization. Clinical management of COVID-19: interim guidance. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19.
10. World Health Organization. Hospital care for adolescents and adults: guidelines for the management of common illnesses with limited resources-Integrated Management of Adolescent and Adult Illness (IMAI). WHO, 2011.
11. Horby P, Lim WS, Emberson JR, etalRECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report. N Engl J Med 2020; doi: 10.1056/NEJMoa2021436. pmid: 32678530
12. Dequin PF, Heming N, Meziani F, etal. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2020; doi: 10.1001/jama.2020.16761.
13. The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020; doi: 10.1001/jama.2020.17022.
14. Tomazini BM, Maia IS, Cavalcanti AB, etal. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial. JAMA 2020; doi: 10.1001/jama.2020.17021.
15. Schandelmaier S, Briel M, Varadhan R, et al. Development of a new Instrument to assess the Credibility of Effect Modification ANalyses (ICEMAN) in randomized controlled trials and meta-analyses. [in submission].
16. Corral L, Bahamonde A, delas Revillas FA, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. MedRxiv 2020.
17. World Health Organization. Q&A: Dexamethasone and COVID-19. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answershub/ q-a-detail/q-a-dexamethasone-and-covid-19.